axitinib

Pfizer pancreatic cancer drug fails, trial halted

New York, January 31: Pfizer Inc., the world's largest drugmaker announced on Friday that it has halted a research work aimed to study the effects of an experimental drug developed to

Pfizer pancreatic cancer drug fails, trial halted

The research in its late stage was put to an end following the report given by an independent monitoring board. The report showed that the drug had no ability to effectively cure pancreatic cancerdefine or enhance the longevity of the patient.

Syndicate content